NCT01724554

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

A Single-center, Open-label Study Evaluating the Impact of Repeat Intravitreal Injections of Aflibercept on Capillary Non-Perfusion (CNP) in Subjects With Proliferative Retinopathy and/or Macular Edema Secondary to Proliferative Diabetic Retinopathy and Central Retinal Venous Occlusive Disease

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Ophthalmic Consultants of Boston · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to look at how effective, safe, and well tolerated Intravitreal Aflibercept Injection is in subjects with Central Retinal Vein Occlusion (CRVO) or Proliferative Diabetic Retinopathy (PDR).

Detailed description

Protocol available upon request.

Conditions

• Central Retinal Vein Occlusion
• Proliferative Diabetic Retinopathy

Interventions

Type	Name	Description
DRUG	Intravitreal Aflibercept Injection	Aflibercept administered to the eye intravitreally either every month or every other month.

Timeline

• Start date: 2012-11-01
• Primary completion: 2014-10-01
• Completion: 2014-10-01
• First posted: 2012-11-09
• Last updated: 2015-05-22

Locations

1 site across 1 country: United States